They were randomly divided into 6 groups. Treatment groups received treatment of BAL+ MARS, BAL+ SPE+ CHDF or BAL+ SPE+HP respectively. Control groups received treatment of MARS, SPE+ CHDF or SPE+HP respectively.

• 选取120例晚期慢性重型肝炎患者,随机均分为6组,治疗组分别接受BAL+MARS、BAL+SPE+CHDF和BAL+SPE+HP治疗,对照组分别接受MARS、SPE+CHDF和SPE+HP治疗。